Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics, Inc. (RAPT) Non-Current Deffered Revenue (2020 - 2022)

RAPT Therapeutics (RAPT) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $241000.0 as the latest value for Q1 2022.

  • Quarterly Non-Current Deffered Revenue fell 75.48% to $241000.0 in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $241000.0 through Mar 2022, down 75.48% year-over-year, with the annual reading at $2.2 million for FY2021, 1.6% down from the prior year.
  • Non-Current Deffered Revenue hit $241000.0 in Q1 2022 for RAPT Therapeutics, down from $2.2 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $2.2 million in Q1 2020 to a low of $241000.0 in Q1 2022.
  • Historically, Non-Current Deffered Revenue has averaged $1.5 million across 3 years, with a median of $1.8 million in 2020.
  • Biggest five-year swings in Non-Current Deffered Revenue: rose 20.62% in 2021 and later plummeted 75.48% in 2022.
  • Year by year, Non-Current Deffered Revenue stood at $2.2 million in 2020, then fell by 1.6% to $2.2 million in 2021, then crashed by 88.79% to $241000.0 in 2022.
  • Business Quant data shows Non-Current Deffered Revenue for RAPT at $241000.0 in Q1 2022, $2.2 million in Q4 2021, and $745000.0 in Q3 2021.